- Home
- NOV vs LEGN Comparison
NOV vs LEGN Comparison
Compare NOV & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NOV | LEGN |
|---|---|---|
| Founded | 1862 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.9B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NOV | LEGN |
|---|---|---|
| Price | $15.74 | $21.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | $16.08 | ★ $69.58 |
| AVG Volume (30 Days) | ★ 3.7M | 2.6M |
| Earning Date | 02-03-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.00 | N/A |
| Revenue | ★ $8,775,000,000.00 | $909,045,000.00 |
| Revenue This Year | N/A | $68.83 |
| Revenue Next Year | N/A | $51.27 |
| P/E Ratio | $15.73 | ★ N/A |
| Revenue Growth | N/A | ★ 74.75 |
| 52 Week Low | $10.84 | $21.19 |
| 52 Week High | $16.96 | $45.30 |
Technical Indicators
Market Signals| Indicator | NOV | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.56 | 25.47 |
| Support Level | $15.29 | $21.19 |
| Resistance Level | $16.96 | $28.97 |
| Average True Range (ATR) | 0.49 | 1.27 |
| MACD | -0.11 | -0.26 |
| Stochastic Oscillator | 33.94 | 9.13 |
Price Performance
Historical ComparisonAbout NOV NOV Inc.
NOV (formerly National Oilwell Varco) is a leading supplier of oil and gas drilling rig equipment and products, such as downhole tools, drill pipe, and well casing. The company operates on a global scale, with international markets contributing nearly two thirds of its annual revenue.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.